Combined hormonal contraceptives: Prescribing patterns, compliance, and benefits versus risks

Therapeutic Advances in Drug Safety

Volumn 5, Issue 5, 2014, Pages 201-213

  Brynhildsen, Jan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

benefits; combined hormonal contraceptives; compliance; side effects

Indexed keywords

DROSPIRENONE; ESTROGEN; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACNE VULGARIS; ARTERY THROMBOSIS; CANCER RISK; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONTRACEPTIVE PATCH; DRUG EFFICACY; DRUG FORMULATION; DYSMENORRHEA; ENDOMETRIUM CANCER; FAMILY HISTORY; FEAR; FEMALE FERTILITY; HEART INFARCTION; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; LIFE EXPECTANCY; MEDICAL INFORMATION; MEDICATION COMPLIANCE; MENORRHAGIA; META ANALYSIS (TOPIC); MORBIDITY; OVARY CANCER; OVARY CYST; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; UNWANTED PREGNANCY; VAGINA RING; VENOUS THROMBOEMBOLISM; WESTERN EUROPE;

EID: 84907217214     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614548857     Document Type: Review

References (87)

1. Abma J. Chandra A. Mosher W. Peterson L. Piccinino L. (1997) Fertility, family planning, and women–s health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23: 1–114.
2. American College of Obstetricians and Gynecologists (2012) Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 120: 983–988.
3. Appleby P. Beral V. Berrington de González A. Colin D. Franceschi S. Goodhill A. (2007) International Collaboration of Epidemiological Studies of Cervical Cancer, Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370: 1609–1621.
4. Archer D. Jensen J. Johnson J. Borisute H. Grubb G. Constantine G. (2006) Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 74: 439–445.
5. Archer D. Kovalevsky G. Ballagh S. Grubb G. (2009) Ovarian activity and safety of a novel levonorgestrel/etinyl estradiol continuous oral contraceptive regimen. Contraception 80: 245–253.
6. Beral V. Doll R. Hermon C. Peto R. Reeves G. (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371: 303–314.
7. Bergendal A. Bremme. K. Hedenmalm K. Lärfars G. Odeberg J. Persson I. (2012) Risk factors for venous thromboembolism in pre- and postmenopausal women. Thromb Res 130: 596–601.
8. Bosetti C. Bravi F. Negri E. La Vecchia C. (2009) Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 15: 489–498.
9. Böttiger L. Boman G. Eklund G. Westerholm B. (1980) Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 24: 1097–1101.
10. Christin-Maitre S. Serfaty D. Chabbert-Buffet N. Ochsenbein E. Chassard D. Thomas J. (2011) Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod 26: 1338–1347.
11. Cibula D. Gompel A. Mueck A. La Vecchia C. Hannaford P. Skouby S. (2010) Hormonal contraception and risk of cancer. Human Reproduction Update 16: 631–650.
12. Colditz G. Rosner B. Speizer F. (1996) Risk factors for breast cancer according to family history of breast cancer. For the Nurses– Health Study Research Group. J Natl Cancer Inst 88: 365–371.
13. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis on individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–1727.
14. Cosmi B. Legnani C. Bernardi F. Coccheri S. Palareti G. (2003) Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 163: 1105–1109.
15. Dayan N. Holcroft C. Tagalakis V. (2011) The risk of venous thrombosis, including cerebral vein thrombosis among women with thrombophilia sand oral contraceptive use; a meta-analysis. Clin Appl Thromb Hemost 217: E141.
16. Dinger J. Assmann A. Möhner S. Minh T. (2010a) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health 36: 123–129.
17. Dinger J. Heinemann L. Kuhl-Habich D. (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observation. Contraception 75: 344–354.
18. Dinger J. Minh T. Buttmann N. Bardenheur K. (2011) Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 117: 33–40.
19. Dinger J. Moehner S. Do Minh T. (2010b) Early use effects on the risk of venous thromboembolism after initiation of oral contraceptive use. Eur J Contracept Reprod Health Care 15(Suppl. 1): 43.
20. Djerassi C. (1992) The pill, Pygmy Chimps, and degas– Horse. Basic Books: New York.
21. Edelman A. Koontz S. Nichols M. Jensen J. (2006) Continuous oral contraceptives. Are bleeding patterns dependent on the hormones given? Obstet Gynecol 107: 657–65.
22. European Medicines Agency (2013) Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation. EMA/709120/2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001969.jsp&mid=WC0b01ac058004d5c1
23. Fernandez E. La Vecchia C. Balducci A. Chatenoud L. Franceschi S. Negri E. (2001) Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 84: 722.
24. Foster D. Parvataneni R. de Bocanegra H. Lewis C. Bradsberry M. Darney P. (2006) Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 108: 1107–1114.
25. Fraser I. Romer T. Parke S. Zeun S. Mellinger U. Machlitt A. (2011) Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 26: 2698–2708.
26. Frederick C. Edelman A. Carlson N. (2011) Extended-use oral contraceptives and medically induced amenorrhea: attitudes, knowledge and prescribing habits of physicians. Contraception 84: 384–389.
27. Gallo M. Lopez L. Grimes D. Carayon F. Schulz K. Helmerhorst F. (2014) Combination contraceptives: effects on weight. Cochrane Database Syst Rev 1: CD003987. DOI: 10.1002/14651858.CD003987.pub5.
28. Gierisch J. Coeytaux R. Urrutia R. Havrilesky L. Moorman P. Lowery W. (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 22: 1931–1943.
29. Goldzieher J. (1990) Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet Gynecol 163: 318.
30. Grabrick D. Hartmann L. Cerhan J. Vierkant R. Therneau T. Vachon C. (2000) Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284: 1791–1798.
31. Grimes D. Stuart G. Levi E. (2012) Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 120: 889–895.
32. Guttmacher Institute (2013) Contraception in the United States. http://www.guttmacher.org/pubs/fb_contr_use.html
33. Hannaford P. Selvaraj S. Elliott A. Angus V. Iversen L. Lee A. (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner–s oral contraception study. BMJ 335: 651.
34. Hansson P. Sörbo J. Eriksson H. (2000) Recurrent venous thromboembolism after deep vein thrombosis. Arch Int Med 160: 769–774.
35. Harada T. Momoeda M. Taketani Y. Hoshiai H. Terakawa N. (2008) Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled double-blind, randomized trial. Fertil Steril 90: 1583–1588.
36. Havrilesky L. Gierisch J. Moorman P. Coeytaux R. Urrutia R. Lowery W. (2013) Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess 212: 1–514.
37. Heikinheimo O. Gissler M. Suhonen S. (2008) Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception 78: 149–154.
38. Holt V. Daling J. McKnight B. Moore D. Stergachis A. Weiss N. (1992) Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obetst Gynecol 79: 529–533.
39. Jensen J. Parke S. Mellinger U. Machlitt A. Fraser I. (2011) Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 117(4): 777–787.
40. Josefsson A. Wiréhn A. Lindberg M. Foldemo A. Brynhildsen J. (2013) Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010. BMJ Open 18, 3(10): e003401. DOI: 10.1136/bmjopen-2013-003401.
41. Lanes S. Birmann B. Walker A. Singer S. (1992) Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 166: 956–961.
42. Langston A. Joslin-Roher S. Westhoff C. (2014) Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice. Contraception 89: 103–108.
43. Larsson G. Milsom I. Lindstedt G. Rybo G. (1992) The influence of a low dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 46: 327–334.
44. Larsson M. Tydén T. Hanson U. Häggström-Nordin E. (2007) Contraceptive use and associated factors among Swedish high school students. J Contracept Reprod Health Care 12: 119–124.
45. Lawrie T. Helmerhorst F. Maitra N. Kulier R. Bloemenkamp K. Gülmezoglu A. (2011) Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 11: CD004861.
46. Lidegaard Ø. Milsom I. Geirsson R. Skjeldestad F. (2012) Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 91: 769–778.
47. Lindh I. Blohm F. Andersson-Ellström E. Milsom I. (2009) Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Contraception 80: 163–169.
48. Longatto-Filho A. Hammes L. Sarian L. Roteli-Martins C. Derchain S. Eržen M. (2011) Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest 71: 93–103.
49. Maitra N. Kulier R. Bloemenkamp K. Helmerhorst F. Gülmezoglu A. (2004) Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 3: CD004861. Update in (2011) Cochrane Database Syst Rev 5: CD004861.
50. Mansour D. Verhoeven C. Sommer W. Weisberg E. Taneepanichskul S. Melis G. (2011) Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 16: 430–443.
51. Margolis K. Adami H. Luo J. Ye W. Weiderpass E. (2007) A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 88: 310–316.
52. Milsom I. Sundell G. Andersch B. (1990) The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 42: 497–506.
53. Mueck A. Seeger H. Rabe T. (2010) Hormonal contraception and risk of endometrial cancer: a systematic review. Endocrine-Related Cancer 17: R263–R271.
54. Murphy P. Brixner D. (2008) Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception 77: 257–263.
55. National Collaborating Centre for Women–s and Children–s Health (2007) Heavy Menstrual Bleeding. Clinical Guideline. National Institute for Health and Clinical Excellence. London, UK: RCOG Press.
56. Nightingale A. Lawrenson R. Simpson E. Williams T. MacRae K. Farmer R. (2000) The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 5: 265–274.
57. O–Brien S. Kaizar E. Gold M. (2008) Trends in prescribing patterns of hormonal contraceptives for adolescents. Contraception 77: 264–269.
58. Odlind V. Milsom I. Persson I. Victor A. (2002) Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 81: 482–490.
59. Paulen M. Zapata L. Cansino C. Curtis K. Jamieson D. (2010) Contraceptive use among women with a history of bariatric surgery: a systematic review. Contraception 82: 86–94.
60. Potter L. Oakley D. Leon-Wong E. Canamar R. (1996) Measuring compliance among oral contraceptive users. Fam Plann Perspect 28: 154–158.
61. Potter J. McKinnon S. Hopkins K. Amastae J. Shedlin M. Powers D. (2011) Continuation of prescribed compared with over-the-counter oral contraceptives. Obstet Gynecol 117: 551–557.
62. Robinson J. Plichta S. Weisman C. Nathanson C. Ensminger M. (1992) Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol 166: 578–583.
63. Rosen M. Breitkopf D. Nagamani M. (2003) A randomized controlled trial of second- versus third generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 188: 1158–1160.
64. Schlesselman J. (1997) Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner–s guide to meta-analysis. Human Reproduction 12: 1851–1863.
65. Schürks M. Rist P. Bigal M. Buring J. Lipton R. Kurth T. (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339: b3914.
66. Seval D. Buckley T. Kuehl T. (2011) Attitudes and prescribing patterns of extended-cycle oral contraceptives. Contraception 84: 71–75.
67. Silvera S. Miller A. Rohan T. (2005) Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 16: 1059–1063.
68. Sitruk-Ware R. (2005) New progestagens for contraceptive use. Hum Reprod Update 12: 169–178.
69. Sitruk-Ware R. (2008) Pharmacological profile of progestins. Maturitas 61: 151–157.
70. Sitruk-Ware R. Nath A. (2013) Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab 27: 13–24.
71. Speroff L. Darney P. (2011) The history of contraception. In Speroff L. Darney P. (eds), A clinical guide for contraception. Philadelphia, PA: Lippincott Williams and Wilkins, pp. 19–35.
72. Stidham Hall K. Trussell J. (2012) Types of combined oral contraceptives used by U.S. women. Contraception 86: 659–665.
73. Sucato G. Land S. Murray P. Cecchini R. Gold M. (2011) Adolescents– experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol 24: 197–203.
74. Sulak P. Scow R. Preece C. Riggs M. Kuehl T. (2000) Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95: 261–266.
75. The Economist (1999) Oral contraceptives. The liberator. The Economist http://www.economist.com/node/347484
76. Trussell J. (2011) Contraceptive failure in the United States. Contraception 83: 397–404.
77. United Nations (2007) World contraceptive use. http://www.un.org/esa/population/publications/contraceptive2007/contraceptive2007.htm
78. Vessay M. Metcalfe A. Wells C. McPherson K. Westhoff C. Yeates D. (1987) Ovarian neoplasms, functional ovarian cysts and oral contraceptives. BMJ 295: 1518–1520.
79. Vessey M. Painter R. (2006) Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006: 385–389.
80. Wasiak R. Filonenko A. Vanness D. Law A. Jeddi M. Wittrup-Jensen K. (2012) Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Women–s Health 4: 271–278.
81. Weiderpass E. Adami H. Baron J. Magnusson C. Lindgren A. Persson I. (1999) Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10: 277–284.
82. Westhoff C. Torgal A. Mayeda E. Stanczyk F. Lerner J. Benn E. (2010) Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 116: 275–283.
83. WHO (1996) Collaborative Study of cardiovascular Disease and Steroid Hormone Contraception Ischemic stroke and combined oral contraceptives: results of an international multi-center case-control study. Lancet 348: 498–505.
84. WHO (1997) Collaborative Study of cardiovascular Disease and Steroid Hormone Contraception Acute myocardial infarction and combined oral contraceptives: results of an international multi-center case-control study. Lancet 349: 1202–1209.
85. Wilson N. Laursen M. Lidegaard Ø. (2012) Oral contraception in Denmark 1998–2010. Acta Obstet Gynecol Scand 91: 810–815.
86. Winner B. Peipert J. Zhao Q. Buckel C. Madden T. Allsworth J. (2012) Effectiveness of long-acting reversible contraception. N Engl J Med 366: 1998–2007.
87. Yang L. Kuper H. Sandin S. Margolis K. Chen Z. Adami H. (2009) Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke 40: 1050–1508.